FDA warned Natural Beauty Care Pty Ltd that its OTC drugs are adulterated due to CGMP failures and no finished-product or ingredient testing.
What happened
FDA reviewed records the company submitted after an April 16, 2020 request under section 704(a)(4) of the FD&C Act. The records showed no analytical assay testing of active ingredients for each finished batch before U.S. shipment, no identity testing of incoming active pharmaceutical ingredient, and inadequate stability data. FDA placed all drug products made by the firm on Import Alert 66-40 on March 23, 2021.
What FDA found
The company did not test each finished drug batch for identity and strength of active ingredients before release.
21 CFR 211.165(a)The company did not perform at least one identity test on incoming active ingredient lots before use.
21 CFR 211.84(d)(1)The company lacked adequate stability data, including active-ingredient testing, to support expiration dates.
21 CFR 211.166(a)The company did not have process flow diagrams showing critical control points for each finished drug product.
The company's quality systems were inadequate.
What FDA wants
FDA asks the company to correct the violations promptly and respond in writing within 15 working days with corrective actions and testing plans for all U.S.-bound products. FDA also strongly recommends a qualified CGMP consultant.
Who should pay attention
- U.S. distributors and retailers selling OTC drugs made by this firm
- brands sourcing OTC drug products from Australian manufacturers
- suppliers of active ingredients or contract test labs for this firm
This is a summary. Read the original letter on fda.gov.